Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Papp

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.
Journal of the American Academy of Dermatology|March 22, 2001
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort studyV C Ho, C E Griffiths, J Berth-Jones, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 3, 2013
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 studyA B Kimball, K A Papp, Y Wasfi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 2, 2014
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)K A Papp, K Barber, R Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2015
Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINEK A Papp, K Barber, R Bissonnette, et al.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 18, 2013
Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III studyK A Papp, M Sundaram, Y Bao, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trialK A Papp, A Blauvelt, A B Kimball, et al.
The British Journal of Dermatology|April 27, 2012
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisA B Gottlieb, R G Langley, B E Strober, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.
Journal of the American Academy of Dermatology|March 22, 2001
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort studyV C Ho, C E Griffiths, J Berth-Jones, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 3, 2013
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 studyA B Kimball, K A Papp, Y Wasfi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 2, 2014
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)K A Papp, K Barber, R Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2015
Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINEK A Papp, K Barber, R Bissonnette, et al.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 18, 2013
Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III studyK A Papp, M Sundaram, Y Bao, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trialK A Papp, A Blauvelt, A B Kimball, et al.
The British Journal of Dermatology|April 27, 2012
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisA B Gottlieb, R G Langley, B E Strober, et al.
Pageof 6